8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 2, 2026·SEC
Vanda Pharmaceuticals Inc.(VNDA)Earnings, Financials & Key Ratios
VNDA•NASDAQ
$7.44
$440M mkt cap·Price updated May 6, 2026
AboutVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Show more
- Revenue$216M+8.7%
- EBITDA-$139M-328.1%
- Net Income-$220M-1066.5%
- EPS (Diluted)-3.74-1068.8%
- Gross Margin93.96%-0.4%
- EBITDA Margin-64.44%-293.8%
- Operating Margin-69.95%-242.0%
- Net Margin-102.02%-973.0%
- ROE-50.93%-1359.9%
- ROIC-32.23%-358.2%
- Debt/Equity0.04+68.1%
VNDA Key Insights
Vanda Pharmaceuticals Inc. (VNDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VNDA Price & Volume
Vanda Pharmaceuticals Inc. (VNDA) stock price & volume — 10-year historical chart
Loading chart...
VNDA Growth Metrics
Vanda Pharmaceuticals Inc. (VNDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.99%
5 Years-2.73%
3 Years-5.29%
TTM8.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1066.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1046.63%
Return on Capital
10 Years-3.36%
5 Years-6.73%
3 Years-14.47%
Last Year-33.59%
VNDA Recent Earnings
Vanda Pharmaceuticals Inc. (VNDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (73%)●Beat Revenue 3/12 qtrs (27%)
Q1 2026Latest
Feb 11, 2026EPS
$0.46
Est $2.18
+78.9%
Revenue
$57M
Est $59M
-3.5%
Q4 2025
Oct 29, 2025EPS
$0.38
Est $0.31
-22.6%
Revenue
$56M
Est $59M
-5.1%
Q3 2025
Jul 31, 2025EPS
$0.46
Est $0.34
-35.3%
Revenue
$53M
Est $59M
-10.5%
Q2 2025
May 7, 2025EPS
$0.50
Est $0.55
+9.1%
Revenue
$50M
Est $45M
+10.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 11, 2026 | $0.46vs $2.18+78.9% | $57Mvs $59M-3.5% |
| Q4 2025 | Oct 29, 2025 | $0.38vs $0.31-22.6% | $56Mvs $59M-5.1% |
| Q3 2025 | Jul 31, 2025 | $0.46vs $0.34-35.3% | $53Mvs $59M-10.5% |
| Q2 2025 | May 7, 2025 | $0.50vs $0.55+9.1% | $50Mvs $45M+10.9% |
Based on last 12 quarters of dataView full earnings history →
VNDA Peer Comparison
Vanda Pharmaceuticals Inc. (VNDA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 AVPT | 2.22B | 10.27 | 68.47 | 26.93% | 8.3% | 7.95% | 0.02 |
Compare VNDA vs Peers
Vanda Pharmaceuticals Inc. (VNDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VNDA Income Statement
Vanda Pharmaceuticals Inc. (VNDA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 165.08M | 193.12M | 227.19M | 248.17M | 268.68M | 254.38M | 192.64M | 198.77M | 216.1M |
| Revenue Growth % | 13.06% | 16.98% | 17.64% | 9.23% | 8.27% | -5.32% | -24.27% | 3.18% | 8.72% |
| Cost of Goods Sold | 17.85M | 20.51M | 24.49M | 23.36M | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M |
| COGS % of Revenue | 10.81% | 10.62% | 10.78% | 9.41% | 9.54% | 9.55% | 7.68% | 5.69% | 6.04% |
| Gross Profit | 147.24M▲ 0% | 172.61M▲ 17.2% | 202.7M▲ 17.4% | 224.8M▲ 10.9% | 243.05M▲ 8.1% | 230.1M▼ 5.3% | 177.84M▼ 22.7% | 187.46M▲ 5.4% | 203.06M▲ 8.3% |
| Gross Margin % | 89.19% | 89.38% | 89.22% | 90.59% | 90.46% | 90.45% | 92.32% | 94.31% | 93.96% |
| Gross Profit Growth % | 21.38% | 17.23% | 17.43% | 10.9% | 8.12% | -5.33% | -22.71% | 5.41% | 8.32% |
| Operating Expenses | 164.14M | 150.87M | 179.89M | 197.56M | 200.89M | 223.77M | 191.8M | 228.12M | 354.23M |
| OpEx % of Revenue | 99.43% | 78.12% | 79.18% | 79.61% | 74.77% | 87.97% | 99.56% | 114.76% | 163.92% |
| Selling, General & Admin | 123.84M | 105.75M | 129.74M | 140.51M | 124.05M | 136.49M | 112.88M | 146.41M | 237.95M |
| SG&A % of Revenue | 75.02% | 54.76% | 57.11% | 56.62% | 46.17% | 53.65% | 58.6% | 73.66% | 110.11% |
| Research & Development | 38.55M | 43.59M | 48.65M | 55.58M | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
| R&D % of Revenue | 23.35% | 22.57% | 21.41% | 22.39% | 28.05% | 33.72% | 39.88% | 37.45% | 50.56% |
| Other Operating Expenses | 1.47M | 3.61M | 1.5M | 1.48M | 1.48M | 1.52M | 2.09M | 7.27M | 7.01M |
| Operating Income | -16.9M▲ 0% | 21.74M▲ 228.6% | 22.81M▲ 4.9% | 27.24M▲ 19.4% | 42.16M▲ 54.8% | 6.33M▼ 85.0% | -13.95M▼ 320.4% | -40.66M▼ 191.4% | -151.17M▼ 271.8% |
| Operating Margin % | -10.24% | 11.26% | 10.04% | 10.98% | 15.69% | 2.49% | -7.24% | -20.46% | -69.95% |
| Operating Income Growth % | 8.98% | 228.6% | 4.93% | 19.42% | 54.8% | -84.99% | -320.45% | -191.43% | -271.79% |
| EBITDA | -13.92M | 24.69M | 25.7M | 30.1M | 45.01M | 9.06M | -10.94M | -32.53M | -139.25M |
| EBITDA Margin % | -8.43% | 12.79% | 11.31% | 12.13% | 16.75% | 3.56% | -5.68% | -16.36% | -64.44% |
| EBITDA Growth % | -107.65% | 277.41% | 4.08% | 17.12% | 49.51% | -79.86% | -220.75% | -197.28% | -328.1% |
| D&A (Non-Cash Add-back) | 2.98M | 2.96M | 2.89M | 2.86M | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M |
| EBIT | -16.9M | 21.74M | 22.81M | 31.66M | 42.16M | 6.33M | -13.95M | -40.66M | -151.17M |
| Net Interest Income | 0 | 0 | 6.22M | 4.42M | 199K | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 6.22M | 4.42M | 199K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.47M | 3.61M | 6.22M | 4.42M | 199K | 4.97M | 20.29M | 17.74M | 12.52M |
| Pretax Income | -15.43M▲ 0% | 25.35M▲ 264.3% | 29.03M▲ 14.5% | 31.66M▲ 9.0% | 42.36M▲ 33.8% | 11.3M▼ 73.3% | 6.34M▼ 43.9% | -22.92M▼ 461.6% | -138.65M▼ 504.9% |
| Pretax Margin % | -9.35% | 13.12% | 12.78% | 12.76% | 15.77% | 4.44% | 3.29% | -11.53% | -64.16% |
| Income Tax | 136K | 138K | -86.53M | 8.32M | 9.21M | 5.03M | 3.83M | -4.02M | 81.83M |
| Effective Tax Rate % | -0.88% | 0.54% | -298.07% | 26.28% | 21.74% | 44.47% | 60.42% | 17.54% | -59.02% |
| Net Income | -15.57M▲ 0% | 25.21M▲ 261.9% | 115.55M▲ 358.4% | 23.34M▼ 79.8% | 33.15M▲ 42.1% | 6.28M▼ 81.1% | 2.51M▼ 60.0% | -18.9M▼ 853.3% | -220.47M▼ 1066.5% |
| Net Margin % | -9.43% | 13.05% | 50.86% | 9.4% | 12.34% | 2.47% | 1.3% | -9.51% | -102.02% |
| Net Income Growth % | 13.56% | 261.93% | 358.4% | -79.8% | 42.06% | -81.07% | -60.02% | -853.29% | -1066.53% |
| Net Income (Continuing) | -15.57M | 25.21M | 115.55M | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | -220.47M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.35▲ 0% | 0.48▲ 237.1% | 2.11▲ 339.6% | 0.42▼ 80.1% | 0.58▲ 38.1% | 0.11▼ 81.0% | 0.04▼ 60.4% | -0.32▼ 833.9% | -3.74▼ 1068.8% |
| EPS Growth % | 14.63% | 237.14% | 339.58% | -80.09% | 38.1% | -81.03% | -60.36% | -833.94% | -1068.75% |
| EPS (Basic) | -0.35 | 0.50 | 2.17 | 0.43 | 0.60 | 0.11 | 0.04 | -0.32 | -3.74 |
| Diluted Shares Outstanding | 44.74M | 53.05M | 54.85M | 55.19M | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M |
| Basic Shares Outstanding | 44.48M | 50.86M | 53.14M | 54.43M | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
VNDA Balance Sheet
Vanda Pharmaceuticals Inc. (VNDA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 169.86M | 299.13M | 354.14M | 409.14M | 478.3M | 519.29M | 432.95M | 438.89M | 347.26M |
| Cash & Short-Term Investments | 143.41M | 257.36M | 312.13M | 367.74M | 432.81M | 466.86M | 388.26M | 374.64M | 263.85M |
| Cash Only | 33.63M | 61.01M | 45.07M | 61.03M | 52.07M | 135.03M | 135.82M | 102.32M | 84.85M |
| Short-Term Investments | 109.79M | 196.35M | 267.06M | 306.71M | 380.74M | 331.83M | 252.44M | 272.33M | 179M |
| Accounts Receivable | 17.6M | 28.78M | 26.37M | 30.04M | 32.47M | 33.51M | 34.16M | 47.1M | 54.58M |
| Days Sales Outstanding | 38.92 | 54.4 | 42.36 | 44.18 | 44.11 | 48.08 | 64.71 | 86.49 | 92.18 |
| Inventory | 840K | 994K | 1.14M | 1.28M | 1.02M | 1.19M | 1.36M | 1.73M | 1.85M |
| Days Inventory Outstanding | 17.18 | 17.69 | 16.99 | 20 | 14.6 | 17.95 | 33.48 | 55.68 | 51.82 |
| Other Current Assets | 8M | 0 | 14.5M | 0 | 0 | 17.73M | 9.17M | 15.42M | 26.98M |
| Total Non-Current Assets | 35.57M | 33M | 129.61M | 124.31M | 115.49M | 114.95M | 215.49M | 217.31M | 141.69M |
| Property, Plant & Equipment | 5.31M | 4.42M | 15.04M | 14.6M | 12.38M | 10.97M | 9.14M | 12.68M | 13.51M |
| Fixed Asset Turnover | 31.11x | 43.72x | 15.10x | 17.00x | 21.69x | 23.18x | 21.08x | 15.68x | 15.99x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 26.07M | 24.54M | 23.04M | 21.56M | 20.08M | 18.57M | 121.37M | 114.1M | 117.09M |
| Long-Term Investments | 0 | 600K | 578K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 4.19M | 4.04M | 3.27M | 6.64M | 8.15M | 11.38M | 9.98M | 9.1M | 11.08M |
| Total Assets | 205.43M▲ 0% | 332.13M▲ 61.7% | 483.75M▲ 45.7% | 533.46M▲ 10.3% | 593.79M▲ 11.3% | 634.25M▲ 6.8% | 648.44M▲ 2.2% | 656.2M▲ 1.2% | 488.95M▼ 25.5% |
| Asset Turnover | 0.80x | 0.58x | 0.47x | 0.47x | 0.45x | 0.40x | 0.30x | 0.30x | 0.44x |
| Asset Growth % | -2.35% | 61.68% | 45.65% | 10.28% | 11.31% | 6.81% | 2.24% | 1.2% | -25.49% |
| Total Current Liabilities | 70.36M | 53.02M | 59.51M | 65.94M | 74.42M | 91.44M | 87.7M | 99.98M | 145.16M |
| Accounts Payable | 0 | 0 | 5.9M | 1.05M | 925K | 12.69M | 7.14M | 3.5M | 4.94M |
| Days Payables Outstanding | - | - | 88 | 16.39 | 13.17 | 190.75 | 176.26 | 112.85 | 138.23 |
| Short-Term Debt | 0 | 0 | 2.15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 50.03M | 41.48M | 44.86M | 45.38M | 27.68M | 34.01M | 69.33M | 69.36M | 97.19M |
| Current Ratio | 2.41x | 5.64x | 5.95x | 6.21x | 6.43x | 5.68x | 4.94x | 4.39x | 2.39x |
| Quick Ratio | 2.40x | 5.62x | 5.93x | 6.19x | 6.41x | 5.67x | 4.92x | 4.37x | 2.38x |
| Cash Conversion Cycle | - | - | -28.65 | 47.78 | 45.53 | -124.72 | -78.07 | 29.32 | 5.77 |
| Total Non-Current Liabilities | 3.67M | 3.69M | 13.3M | 14.25M | 14.45M | 15.61M | 15.83M | 17.68M | 16.6M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 12.46M | 11.5M | 10.05M | 8.81M | 7.01M | 8.09M | 7.07M |
| Deferred Tax Liabilities | 100K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.67M | 3.69M | 843K | 2.76M | 4.39M | 6.8M | 8.83M | 9.59M | 9.53M |
| Total Liabilities | 74.04M | 56.71M | 72.8M | 80.19M | 88.86M | 107.05M | 103.53M | 117.66M | 161.76M |
| Total Debt | 0 | 0 | 14.6M | 13.61M | 12.37M | 11.14M | 9.4M | 12.36M | 12.62M |
| Net Debt | -33.63M | -61.01M | -30.47M | -47.42M | -39.7M | -123.89M | -126.42M | -89.96M | -72.23M |
| Debt / Equity | - | - | 0.04x | 0.03x | 0.02x | 0.02x | 0.02x | 0.02x | 0.04x |
| Debt / EBITDA | - | - | 0.57x | 0.45x | 0.27x | 1.23x | - | - | - |
| Net Debt / EBITDA | - | -2.47x | -1.19x | -1.58x | -0.88x | -13.67x | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 131.39M▲ 0% | 275.42M▲ 109.6% | 410.94M▲ 49.2% | 453.27M▲ 10.3% | 504.93M▲ 11.4% | 527.2M▲ 4.4% | 544.91M▲ 3.4% | 538.55M▼ 1.2% | 327.19M▼ 39.2% |
| Equity Growth % | 0.04% | 109.63% | 49.21% | 10.3% | 11.4% | 4.41% | 3.36% | -1.17% | -39.25% |
| Book Value per Share | 2.94 | 5.19 | 7.49 | 8.21 | 8.87 | 9.25 | 9.47 | 9.26 | 5.55 |
| Total Shareholders' Equity | 131.39M | 275.42M | 410.94M | 453.27M | 504.93M | 527.2M | 544.91M | 538.55M | 327.19M |
| Common Stock | 45K | 52K | 54K | 55K | 56K | 57K | 58K | 58K | 59K |
| Retained Earnings | -361.43M | -336.22M | -220.66M | -197.33M | -164.18M | -157.9M | -155.39M | -174.29M | -394.77M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -34K | 1K | 249K | 239K | -175K | -1.19M | -30K | 74K | 629K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VNDA Cash Flow Statement
Vanda Pharmaceuticals Inc. (VNDA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.98M | 29.99M | 45.95M | 51.77M | 64.21M | 31.98M | 12.8M | -15.76M | -109.44M |
| Operating CF Margin % | -1.2% | 15.53% | 20.22% | 20.86% | 23.9% | 12.57% | 6.64% | -7.93% | -50.64% |
| Operating CF Growth % | 75.53% | 1612.15% | 53.23% | 12.68% | 24.03% | -50.19% | -59.98% | -223.09% | -594.56% |
| Net Income | -15.57M | 25.21M | 115.55M | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | -220.47M |
| Depreciation & Amortization | 2.98M | 2.96M | 2.89M | 2.86M | 2.84M | 2.73M | 3.01M | 8.13M | -950K |
| Stock-Based Compensation | 10.46M | 11.67M | 0 | 13.36M | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Deferred Taxes | -426K | -2.22M | -87.77M | 6.19M | 6.75M | 1.13M | -1.29M | -6.48M | 81.44M |
| Other Non-Cash Items | 587K | 167K | 12.14M | 1.71M | 3.37M | -507K | -4.72M | -4.38M | 12.76M |
| Working Capital Changes | -26K | -7.79M | 3.13M | 4.32M | 2.74M | 6.07M | -747K | -6.56M | 8.31M |
| Change in Receivables | 2.52M | -11.21M | 2.34M | -3.77M | -2.47M | -1.09M | -707K | -13.01M | -7.46M |
| Change in Inventory | -1.06M | 70K | -722K | -2.88M | -2.23M | -4.48M | -771K | -29K | -3.47M |
| Change in Payables | 5.95M | -4.88M | 3.51M | 3.76M | 3.04M | 11.79M | -10.98M | 1.71M | 15.82M |
| Cash from Investing | -10.11M | -109.66M | -68.31M | -41.5M | -76.7M | 49.92M | -12.06M | -17.43M | 94.86M |
| Capital Expenditures | -1.66M | -25.37M | -1.02M | -1.79M | -552K | -679K | -383K | -490K | -998K |
| CapEx % of Revenue | 1.01% | 13.14% | 0.45% | 0.72% | 0.21% | 0.27% | 0.2% | 0.25% | 0.46% |
| Acquisitions | 0 | 25M | 0 | 0 | 0 | 0 | -100.67M | -4.23M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 124K | -25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.25M | 107.13M | 6.26M | 5.63M | 3.55M | 734K | 0 | -155K | -2.91M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -155K | -1.99M |
| Equity Issued (Net) | 0 | 100.87M | 6.26M | 5.63M | 3.55M | 734K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 5.25M | 6.26M | 0 | 0 | 0 | 0 | 0 | 0 | -915K |
| Net Change in Cash | -6.8M▲ 0% | 27.41M▲ 503.2% | -16.03M▼ 158.5% | 16.02M▲ 199.9% | -9.02M▼ 156.3% | 82.96M▲ 1020.0% | 792K▼ 99.0% | -33.51M▼ 4330.4% | -17.36M▲ 48.2% |
| Free Cash Flow | -3.65M▲ 0% | 4.62M▲ 226.6% | 44.93M▲ 872.9% | 49.98M▲ 11.2% | 63.66M▲ 27.4% | 31.3M▼ 50.8% | 12.42M▼ 60.3% | -16.25M▼ 230.8% | -110.44M▼ 579.8% |
| FCF Margin % | -2.21% | 2.39% | 19.78% | 20.14% | 23.69% | 12.31% | 6.45% | -8.17% | -51.1% |
| FCF Growth % | 61.65% | 226.62% | 872.89% | 11.24% | 27.37% | -50.83% | -60.33% | -230.83% | -579.76% |
| FCF per Share | -0.08 | 0.09 | 0.82 | 0.91 | 1.12 | 0.55 | 0.22 | -0.28 | -1.87 |
| FCF Conversion (FCF/Net Income) | 0.13x | 1.19x | 0.40x | 2.22x | 1.94x | 5.10x | 5.10x | 0.83x | 0.50x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VNDA Key Ratios
Vanda Pharmaceuticals Inc. (VNDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -13.63% | -11.85% | 12.39% | 33.67% | 5.4% | 6.92% | 1.22% | 0.47% | -3.49% | -50.93% |
| Return on Invested Capital (ROIC) | -16.09% | -13.44% | 10.45% | 5.75% | 5.2% | 7.26% | 1.09% | -2.55% | -7.03% | -32.23% |
| Gross Margin | 83.08% | 89.19% | 89.38% | 89.22% | 90.59% | 90.46% | 90.45% | 92.32% | 94.31% | 93.96% |
| Net Margin | -12.33% | -9.43% | 13.05% | 50.86% | 9.4% | 12.34% | 2.47% | 1.3% | -9.51% | -102.02% |
| Debt / Equity | - | - | - | 0.04x | 0.03x | 0.02x | 0.02x | 0.02x | 0.02x | 0.04x |
| FCF Conversion | 0.45x | 0.13x | 1.19x | 0.40x | 2.22x | 1.94x | 5.10x | 5.10x | 0.83x | 0.50x |
| Revenue Growth | 32.83% | 13.06% | 16.98% | 17.64% | 9.23% | 8.27% | -5.32% | -24.27% | 3.18% | 8.72% |
VNDA SEC Filings & Documents
Vanda Pharmaceuticals Inc. (VNDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
VNDA Frequently Asked Questions
Vanda Pharmaceuticals Inc. (VNDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vanda Pharmaceuticals Inc. (VNDA) reported $216.1M in revenue for fiscal year 2025. This represents a 635877% increase from $0.0M in 2004.
Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 8.7% over the past year. This is steady growth.
Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $220.5M for fiscal year 2025.
Dividend & Returns
Vanda Pharmaceuticals Inc. (VNDA) has a return on equity (ROE) of -50.9%. Negative ROE indicates the company is unprofitable.
Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $110.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More VNDA
Vanda Pharmaceuticals Inc. (VNDA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates